TWO · 6712.TWO
Ever Supreme Bio Technology Co., Ltd
NT$150.50-NT$2.00 (-1.31%)
Ever Supreme Bio Technology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 18.21% below the high.
Loading market information…
TAI · 6949.TW · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pell Bio-Med Technology Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$150.50-NT$2.00 (-1.31%)
Ever Supreme Bio Technology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 18.21% below the high.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$39.55-NT$0.50 (-1.25%)
Locus Cell Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.24% below the high.
NT$12.80-NT$0.55 (-4.12%)
Acepodia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.44% below the high.
NT$33.20-NT$0.60 (-1.78%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
NT$68.20-NT$0.40 (-0.58%)
UnicoCell Biomed Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.82% below the high.
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
